ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

RCUS Arcus Biosciences Inc

16.97
-0.03 (-0.18%)
15 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Arcus Biosciences Inc NYSE:RCUS NYSE Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  -0.03 -0.18% 16.97 17.18 16.43 16.86 1,430,771 01:00:00

Arcus Biosciences Announces New Employment Inducement Grants

24/08/2023 9:35pm

Business Wire


Arcus Biosciences (NYSE:RCUS)
Historical Stock Chart


From Jun 2023 to Jun 2024

Click Here for more Arcus Biosciences Charts.

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted five new employees options to purchase a total of 14,600 shares of the Company’s common stock at an exercise price per share of $23.03, which was the closing price on August 23, 2023, and restricted stock units to acquire a total of 7,300 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has advanced multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 A2a/A2b receptors) and HIF-2α. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com.

Inducement PR

Source: Arcus Biosciences

Investor Inquiries: Pia Banerjee Head of Investor Relations & Strategy (617) 459-2006 pbanerjee@arcusbio.com

Media Inquiries: Holli Kolkey VP of Corporate Communications (650) 922-1269 hkolkey@arcusbio.com

1 Year Arcus Biosciences Chart

1 Year Arcus Biosciences Chart

1 Month Arcus Biosciences Chart

1 Month Arcus Biosciences Chart

Your Recent History

Delayed Upgrade Clock